Dendritic Cells Genetically Engineered to Express Fas Ligand Induce Donor-Specific Hyporesponsiveness and Prolong Allograft Survival

Department of Surgery and Multiorgan Transplant Program, Toronto Hospital Research Institute, University of Toronto, Ontario, Canada.
The Journal of Immunology (Impact Factor: 4.92). 02/2000; 164(1):161-7. DOI: 10.4049/jimmunol.164.1.161
Source: PubMed


Polarization of an immune response toward tolerance or immunity is dictated by the interactions between T cells and dendritic cells (DC), which in turn are modulated by the expression of distinct cell surface molecules, and the cytokine milieu in which these interactions are taking place. Genetic modification of DC with genes coding for specific immunoregulatory cell surface molecules and cytokines offers the potential of inhibiting immune responses by selectively targeting Ag-specific T cells. In this study, the immunomodulatory effects of transfecting murine bone marrow-derived DC with Fas ligand (FasL) were investigated. In this study, we show that FasL transfection of DC markedly augmented their capacity to induce apoptosis of Fas+ cells. FasL-transfected DC inhibited allogeneic MLR in vitro, and induced hyporesponsiveness to alloantigen in vivo. The induction of hyporesponsiveness was Ag specific and was dependent on the interaction between FasL on DC and Fas on T cells. Finally, we show that transfusion of FasL-DC significantly prolonged the survival of fully MHC-mismatched vascularized cardiac allografts. Our findings suggest that DC transduced with FasL may facilitate the development of Ag-specific unresponsiveness for the prevention of organ rejection. Moreover, they highlight the potential of genetically engineering DC to express other genes that affect immune responses.

10 Reads
  • Source
    • "By binding the cell death receptor Fas (CD95), Fas ligand participates in the maintenance of peripheral T-cell tolerance and maintenance of immune privilege in certain organs. DCs expressing transgenic Fas ligand inhibited antigen-specific T-cell responsiveness, prolonging the survival of fully MHC-mismatched cardiac allografts in some studies [215, 216], but not in others [217, 218]. Mouse tolerogenic DCs generated with antisense ODN against the costimulatory molecules CD40, CD80, and CD86 remained costimulatory deficient in vivo, even after 3 weeks of injection [219]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To avoid immune rejection, allograft recipients require drug-based immunosuppression, which has significant toxicity. An emerging approach is adoptive transfer of immunoregulatory cells. While mature dendritic cells (DCs) present donor antigen to the immune system, triggering rejection, regulatory DCs interact with regulatory T cells to promote immune tolerance. Intravenous injection of immature DCs of either donor or host origin at the time of transplantation have prolonged allograft survival in solid-organ transplant models. DCs can be treated with pharmacological agents before injection, which may attenuate their maturation in vivo. Recent data suggest that injected immunosuppressive DCs may inhibit allograft rejection, not by themselves, but through conventional DCs of the host. Genetically engineered DCs have also been tested. Two clinical trials in type-1 diabetes and rheumatoid arthritis have been carried out, and other trials, including one trial in kidney transplantation, are in progress or are imminent.
    Journal of Transplantation 10/2013; 2013:761429. DOI:10.1155/2013/761429
  • Source
    • "Selective inducing apoptosis of antigen-specific T cells by APCs genetically modified to express death ligand (e.g., FasL and TRAIL) is an alternative way to downregulate antigen-specific T-cell responses. DCs genetically modified to express FasL can induce donor-specific T-cell hyporesponsiveness to alloantigen and facilitate allograft survival [41]. FasL-expressing DCs are also able to suppress collagen-reactive T cells and inhibit the progression of murine CIA after systemic injection [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rheumatoid arthritis (RA) is a chronic autoimmune disease and one of the leading causes of disability in the USA. Although certain biological therapies, including protein and antibodies targeting inflammatory factors such as the tumor necrosis factor, are effective in reducing symptoms of RA, these treatments do not reverse disease. Also, although novel gene therapy approaches have shown promise in preclinical and clinical studies to treat RA, it is still unclear whether gene therapy can be readily and safely applied to treat the large number of RA patients. Recently, nanosized, endocytic-derived membrane vesicles "exosomes" were demonstrated to function in cell-to-cell communication and to possess potent immunoregulatory properties. In particular, immunosuppressive DC-derived exosomes and blood plasma- or serum-derived exosomes have shown potent therapeutic effects in animal models of inflammatory and autoimmune disease including RA. This paper discusses the current knowledge on the production, efficacy, mechanism of action, and potential therapeutic use of immunosuppressive exosomes for arthritis therapy.
    International Journal of Rheumatology 03/2012; 2012(10):573528. DOI:10.1155/2012/573528
  • Source
    • "first the cells were fixed with paraformaldehyde, then permeabilized with Triton X-100, and analyzed by flow cytometry. The FITC-conjugated AnnexinV and PI staining was used for determination of apoptosis /necrosis as previously described by Min et al. (2000). "
    [Show abstract] [Hide abstract]
    ABSTRACT: CD40-CD154 interaction is an important process for cellular and humoral immunity regulation and can be effective in the body's defense against tumors. In the present study, we evaluated the expression of CD40 in Wehi-164 cell line. CD40 expressions on the cell surface and in the cytoplasm were assessed by flow cytometry and intracellular staining assay, respectively. Also, the mRNA expression was identified by real time-PCR. The obtained results showed the high mRNA and cytoplasmic protein expression of CD40 but no surface expression. These results suggest that the Wehi-164 cell line down regulates expression of CD40 on the surface for evasion of immune system.
    Cytotechnology 05/2010; 62(3):195-9. DOI:10.1007/s10616-010-9277-x · 1.75 Impact Factor
Show more